Fred Fändrich

Professor Fändrich is the Director of the Dept. of Applied Cellular Medicine, at the University Hospital of Schleswig-Holstein, Kiel, Germany and the founder of Blasticon, the owner of a patented technology which monocytes (mature white blood cells) from blood extracted from the veins can be turned into cells with programmable properties such as those in stem cell and in turn be used for diverse applications in diagnostics and treatments.

He is the President of the European Society for Autoimmune Disease (EGAI) and is also one of five opinion leaders, World Transplant Society, Oxford, UK. Up to 2009, Professor Fändrich was a Professor of Surgery specializing in transplantation medicines. He later decided to direct his focus into the field of cellular medicine at the University of Kiel.

Professor Fändrich has been the recipient of many awards including Outstanding Physics Award, University of CA, Riverside, the Rudolf-Pichlmayr-Award for outstanding research in the field of peptide and stem-cell mediated tolerance induction, German Society of Surgery (DGC) and the GEORG-HEBERER-Award, Chiles Foundation Portland, Oregon.

He has published many scientific papers and clinical reviews under references for Transplantation, Oncology, Regenerative and Cellular Medicine, Immunotherapy and made contributions to clinical reference books.

Professor Fändrich travels frequently to Asia to conduct lectures and speak at medical and wellness conferences.